Disseminated Intravascular Coagulation: The Application and Utility of Diagnostic Tests

Ockelford, Paul; Carter, Cedric J.

doi:10.1055/s-2007-1005052

Cited by 20 publications

(2 citation statements)

References 158 publications

(209 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… †Will be sensitive to hypofibrinogenaemias, dysfibrinogenaemias and the presence of heparin but not to the effects of fetal fibrinogen ( Ockelford & Carter, 1982). …”

Section: Screening Tests Of Neonatal Haemostasismentioning

confidence: 99%

The investigation and management of neonatal haemostasis and thrombosis*

2002

View full text Add to dashboard Cite

Summary These guidelines address developmental aspects of neonatal haemostasis and thrombosis, the laboratory investigation of the neonate, and the diagnosis and clinical management of haemostatic and thrombotic conditions occurring in this period (defined as the first 4 weeks of life following birth). Relevant scientific papers were identified by a systematic literature review from Medline 1975–2000 using index terms which incorporated the various component subjects of these guidelines. Further publications were obtained from the references cited and from reviews known to the members of the working party and to the Haemostasis and Thrombosis Task Force. Evidence and graded recommendations presented in these guidelines are in accordance with the US Agency for Health Care Policy and Research, as described in the Appendix. It will be noted that there is a lack of a strong evidence base for many of the recommendations suggested, as the appropriate clinical and laboratory trials have not been and perhaps never will be undertaken in neonates. Most of the recommendations are therefore of Grade C evidence levels IV: higher levels are mentioned specifically throughout the document when relevant.

show abstract

“… †Will be sensitive to hypofibrinogenaemias, dysfibrinogenaemias and the presence of heparin but not to the effects of fetal fibrinogen ( Ockelford & Carter, 1982). …”

Section: Screening Tests Of Neonatal Haemostasismentioning

confidence: 99%

The investigation and management of neonatal haemostasis and thrombosis*

2002

View full text Add to dashboard Cite

show abstract

“…Reductions in AT III below normal values are clinically important and have been associated with disseminated intravascular coagulation, 7,74 venous thrombosis, 15,23,44 hypercoagulability, 4,58 liver dis ease, 6,54 the nephrotic syndrome, 46,49 and major surgery. 9 Certain drugs can also cause a decrease in functional AT III.…”

Section: Clinical Significancementioning

confidence: 99%

Coagulation Testing with the Du Pont aca Discrete Clinical Analyzer

Jf¹,

Ja²,

Ge³

1983

Semin Thromb Hemost

View full text Add to dashboard Cite

Autologous bone marrow transplantation and factor xii, factor vii, and protein c deficiencies report of a new association and its possible relationship to endothelial cell injury

Kaufman

Jones²,

Greenberg

et al. 1990

Cancer

View full text Add to dashboard Cite

Four patients who underwent treatment with high-dose chemotherapy (HDC) and autologous bone marrow transplantation (ABMT) and in whom posttreatment deficiencies of Factor XII and protein C subsequently developed are reported. Factor VII or Factor X deficiencies also developed in several of these patients. Three of these patients experienced chemotherapy-related cardiac, hepatic, or pulmonary toxicity. It is believed by many that endothelial cell injury may be the underlying lesion responsible for these various organ system toxicities seen in the setting of ABMT, although direct evidence of this is lacking. It is proposed that the factor deficiencies described in this report may be an additional consequence of endothelial cell injury or dysfunction. These coagulation factor deficiencies may therefore serve as both a marker to follow these organ system toxicities with and as a useful tool to better study and understand the mechanisms underlying these events. Additionally, deficiencies of either Factor VII or Factor X developed in several patients that were of a sufficient magnitude such that factor replacement therapy would be indicated before any invasive procedures or in the event of significant hemorrhage.

show abstract

Disseminated Intravascular Coagulation: The Application and Utility of Diagnostic Tests

Cited by 20 publications

References 158 publications

The investigation and management of neonatal haemostasis and thrombosis*

The investigation and management of neonatal haemostasis and thrombosis*

Coagulation Testing with the Du Pont aca Discrete Clinical Analyzer

Autologous bone marrow transplantation and factor xii, factor vii, and protein c deficiencies report of a new association and its possible relationship to endothelial cell injury

Contact Info

Product

Resources

About